More essentially, current research demonstrates that the HDAC inhibitor could reverse PELP-mediated suppression of MIR-200 family members, suggesting an uninterrupted association between the HDAC inhibitor and family members of miR-200 in breast tumors [16,17]. The gene discussed is HDAC9; the disease is breast neoplasm.